Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus KEFUROX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus KEFUROX IN PLASTIC CONTAINER.
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER vs KEFUROX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3 in Gram-negative bacteria, leading to cell lysis and death.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
1-2 g IV every 8-12 hours for moderate to severe infections; for febrile neutropenia, 2 g IV every 8 hours.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life ≈2.0–2.3 hours in healthy adults; prolonged to 13–26 hours in severe renal impairment (CrCl <10 mL/min); relevant for dosing interval adjustment.
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic